Ipilimumab retreatment following induction therapy: The expanded access program (EAP) experience

被引：0
|
作者：
Margolin, Kim Allyson
Hamid, Omid
Weber, Jeffrey S.
Pavlick, Anna C.
Hodi, F. Stephen
Amin, Asim
Bennett, Kelly
Michener, Tracy
Minor, David R.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Angeles Clin & Res Inst, Los Angeles, CA USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Comprehens Melanoma Res Ctr, Tampa, FL USA
[4] NYU, Dept Med, Langone Med Ctr, New York, NY 10016 USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Levine Canc Inst, Charlotte, NC USA
[7] Bristol Myers Squibb, Plainsboro, NJ USA
[8] Calif Pacific Ctr Melanoma Res & Treatment, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9041
引用
收藏
页数：1
相关论文
共 50 条
  • [21] EFFICACY AND SAFETY OF IPILIMUMAB REINDUCTION THERAPY PATIENTS WITH PRETREATED ADVANCED MELANOMA PARTICIPATING IN AN EXPANDED ACCESS PROGRAMME (EAP) IN ITALY
    Pigozzo, J.
    Calabro, L.
    Ascierto, P. A.
    De Galitiis, F.
    Ferrucci, P. F.
    Queirolo, P.
    Bernengo, M. G.
    Aglietta, M.
    Mandala, M.
    Del Vecchio, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 369 - 369
  • [22] SAFETY DATA FROM AN EXPANDED ACCESS PROGRAM (EAP) OF NIVOLUMAB (NIVO) IN COMBINATION WITH IPILIMUMAB (IPI) IN PATIENTS WITH ADVANCED MELANOMA (MEL)
    Chapman, Paul B.
    Sznol, Mario
    Lao, Christopher D.
    Gonzalez, Rene
    Daniels, Gregory A.
    Thompson, John A.
    Kudchadkar, Ragini R.
    Sharfman, William H.
    Atkins, Michael B.
    Pavlick, Anna C.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Weber, Jeffrey S.
    Nair, Suresh
    Cowey, Lance
    Lipson, Evan J.
    Lee, Sue
    Avila, Alexandre
    Hodi, Stephen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 119 - 119
  • [23] Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
    Chapman, Paul B.
    Sznol, Mario
    Lao, Christopher
    Gonzalez, Rene
    Daniels, Gregory A.
    Thompson, John A.
    Kudchadkar, Ragini Reiney
    Sharfman, William Howard
    Atkins, Michael B.
    Pavlick, Anna C.
    Infante, Jeffrey R.
    Kim, Kevin
    Weber, Jeffrey S.
    Patel, Sapna Pradyuman
    Nair, Suresh
    Cowey, C. Lance
    Lipson, Evan J.
    Lee, Sue
    Avila, Alexandre
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Implementation of Tofersen Expanded Access Program (EAP) in the US, The Cumulative Experience of Six Academic Centers.
    Ajroud-Driss, Senda
    Babu, Suma
    Harms, Matthew
    Shneider, Neil
    Quinn, Colin
    Arcila-Londono, Ximena
    Bucelli, Robert
    MUSCLE & NERVE, 2023, 68 : S59 - S60
  • [25] Pembrolizumab expanded access program (EAP) in Spain: clinical activity.
    Arance, Ana
    Piulats, Josep M.
    Rodas, Ivan Marquez
    Manzano, Jose Luis
    Berrocal, Alfonso
    Algarra, Salvador Martin
    Crespo, Guillermo
    Rodriguez, Delvys
    Guerrero, Miguel Angel Berciano
    Soria, Ainara
    Ruiz, Elisabeth Perez
    Castano, Almudena Garcia
    Montagut, Clara
    Puertolas, Teresa
    Aguado, Carlos
    Royo, Maria Angeles
    Blanco, Remei
    Munoz-Couselo, Eva
    Sanchis, Pilar Mut
    Gonzalez-Cao, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
    Anna Maria Di Giacomo
    Riccardo Danielli
    Luana Calabrò
    Erica Bertocci
    Chiara Nannicini
    Diana Giannarelli
    Angelo Balestrazzi
    Francesco Vigni
    Valentina Riversi
    Clelia Miracco
    Maurizio Biagioli
    Maresa Altomonte
    Michele Maio
    Cancer Immunology, Immunotherapy, 2011, 60 : 467 - 477
  • [27] Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma
    Krajsova, Ivana
    Arenberger, Petr
    Lakomy, Radek
    Kubala, Eugen
    Brezinova, Ivana
    Poprach, Alexandr
    Stastny, Marek
    Muzik, Jan
    Melichar, Bohuslav
    ANTICANCER RESEARCH, 2015, 35 (11) : 6303 - 6310
  • [28] Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
    Di Giacomo, Anna Maria
    Danielli, Riccardo
    Calabro, Luana
    Bertocci, Erica
    Nannicini, Chiara
    Giannarelli, Diana
    Balestrazzi, Angelo
    Vigni, Francesco
    Riversi, Valentina
    Miracco, Clelia
    Biagioli, Maurizio
    Altomonte, Maresa
    Maio, Michele
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (04) : 467 - 477
  • [29] Durable remissions with Ipilimumab in pretreated metastatic malignant melanoma (MMM) patients (pts): Results of a South African Expanded Access Program (EAP).
    Vorobiof, Daniel A.
    Rapoport, Bernardo Leon
    Dreosti, Lydia Mary
    Nosworthy, Adam L.
    McAdam, Georgina Laird
    Jordaan, Johann Petrus
    Donato, Bonnie M. K.
    Qatami, Lara
    Duvenhage, Hennie
    Stander, Tienie
    Bergh, Margreet
    De Beer, Janetta
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Durable remissions with ipilimumab in pretreated metastatic malignant melanoma (MMM) patients (pts). Results of a South African Expanded Access Program (EAP)
    Rapoport, B.
    Vorobiof, D.
    Dreosti, L.
    Nosworthy, A.
    McAdam, G.
    Jordaan, A. P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S674 - S674
12345